INTRODUCTION {#S1}
============

Mutations in isocitrate dehydrogenase 1 (*IDH1*) and 2 (*IDH2*) are prevalent in acute myeloid leukemias, gliomas, sarcomas, and other tumors ([@R34]; [@R38]; [@R44]; [@R57]). These gain-of-function mutations modify the activity of IDH1 and IDH2 such that the major reaction catalyzed is the NADPH-mediated reduction of a-ketoglutarate (aKG) to (D)2-hydroxyglutarate (D2HG) ([@R10]; [@R54]). In addition, mutant IDH1 and IDH2 exhibit decreased activity for the wild-type (WT) reaction, which reversibly interconverts isocitrate and NADP+ with aKG, CO~2~, and NADPH ([@R54]). Therefore, cells harboring such IDH mutations exhibit metabolic reprogramming to compensate for these changes in enzyme activity.

Under hypoxic conditions, IDH1-mutant cells exhibit increased oxidative TCA flux, respiration, and decreased growth ([@R17]). Although *IDH1*-mutant cells do not increase reductive carboxylation in hypoxia to the same extent as cells expressing only WT IDH1, mitochondrial metabolism and redox pathways are rewired to support the growth of mutant IDH1 cells in culture and *in vivo* ([@R5]; [@R11]). More generally, IDH1-mutant cells exhibit various defects in mitochondrial metabolism, which may be therapeutically exploited by targeting NAMPT, BCL2, or other targets ([@R6]; [@R21]; [@R43]; [@R47]). These results demonstrate that *IDH1*-mutant cells exhibit similar metabolism to cells expressing WT *IDH1* under basal conditions but altered metabolic states under conditions of bioenergetic or redox stress.

IDH1 is not thought to be a major source of NADPH in mammals ([@R12]). *IDH1*^−/−^mice exhibit phenotypes only in select tissues or in response to specific stresses (i.e., nutrient deprivation) ([@R58]). In culture, overall IDH-mediated exchange flux is high, and the reverse reaction can support lipogenesis or compartment-specific redox maintenance in cancer cells under conditions of metabolic stress ([@R23]; [@R36]; [@R55]). The oxidative pentose phosphate pathway (oxPPP) is classically thought to be the primary pathway through which NADPH is regenerated in the cytosol ([@R45]). Recent studies using ^2^H tracing support this concept, whereby the oxPPP exhibits the highest contribution to cytosolic NADPH regeneration supporting biosynthesis([@R62], 2017). Cell lines engineered to express mutant IDH1 enzymes exhibit increased oxPPP flux and differential lipid synthesis ([@R16]), highlighting the importance of this pathway. On the other hand, knockout of oxPPP enzymes is particularly deleterious for cancer cell growth ([@R65]).

To better understand how mutations in *IDH1* influence NADPH metabolism, we applied ^13^C and ^2^H metabolic flux analysis to an isogenic panel of fibrosarcoma cell lines that endogenously express IDH1^+/R132C^ or were engineered to express a WT, R132C mutant, or enzymatically dead IDH1 enzyme after knocking out the original mutant allele ([@R33]). These cell lines recapitulate changes in anchorage-independent growth driven by mutant IDH1 ([@R33]) as well as the metabolic defects documented to occur under hypoxia. 2HG production and secretion were a major sink of NADPH in IDH1^+/R132C^ cells, though cells could sufficiently compensate by modulating oxPPP flux. However, in lipid-deficient conditions D2HG production and secretion presented a metabolic liability that negatively affected *de novo lipogenic flux and in vitro* cell growth. These results demonstrate that IDH1 R132 mutations may be considered a significant redox liability in tumors, rendering them susceptible to metabolic stress.

RESULTS {#S2}
=======

Use of Genetically Engineered HT1080 Fibrosarcoma Cell Lines to Dissect Enzymatic Functions of IDH1 and Mutant IDH1 {#S3}
-------------------------------------------------------------------------------------------------------------------

D2HG production in cells harboring R132 mutations in *IDH1* is dramatically increased and has an established role in tumorigenesis.Hereweinterrogatedredoxmetabolismoffibrosarcomacells using a genetically engineered panel of cell lines that recapitulate the metabolic reprogramming associated with oncogenic *IDH1* mutations. In this system, the mutant *IDH1* allele was knocked out of HT1080 fibrosarcoma cells (+/R132C), generating HT1080 cells heterozygous cell line for *IDH1* (+/-). Next, an isogenic IDH1-mutant panel was then re-expressed in the HT1080 *IDH1* (+/-) cell line generating vector control (PB; +/-), engineered WT *IDH1* (+/+), re-expressed *IDH1*-mutant (R132C; +/R132C), and catalytically dead double-mutant (T77A; +/ R132C-T77A) cell lines ([@R33]). As depicted in [Figure 1A](#F1){ref-type="fig"}, these cell lines exhibit distinct reprogramming of IDH1 enzymatic activity such that PB and WT cells maintain endogenous activity and do not readily produce D2HG, R132C mutants have reduced endogenous IDH1 activity and produce D2HG, while T77A mutants have reduced endogenous IDH1 activity and do not accumulate D2HG(Maetal.,2015).Therefore,wecouldinterrogatethedistinct metabolic consequences of modulating WT IDH1 activity as well as neomorphic D2HG production by IDH1 R132C.

We first quantified per cell organic and amino acid abundances in each cell type, observing R132C-specific changes in abundance of glutamine and aKG ([Figure 1B](#F1){ref-type="fig"}). In addition, we detected increased levels of non-essential amino acids (i.e., Glu, Ser, Pro, and Asp), consistent with previously described increases in glutaminolysis in *IDH1*-mutant cells ([@R17]; [@R43]). We also observed elevated levels of Gly3P in R132C cells, suggesting that mitochondrial and/or cytosolic redox metabolism is perturbed in D2HG-producing cells ([Figure 1B](#F1){ref-type="fig"}). On the other hand, intracellular abundance of most glycolytic metabolites, TCA metabolites, and other amino acids were not perturbed by altered IDH1 enzymatic function ([Figure 1B](#F1){ref-type="fig"}). These results are consistent with general dispensability of IDH1 function in basal culture conditions.

Next, we characterized alterations in IDH flux in this isogenic fibrosarcoma cell line panel. Under conditions of hypoxia, IDH1 and IDH2 can support de *novo* lipogenesis by catalyzing the reductive carboxylation of aKG to isocitrate, which is subsequently metabolized to citrate and acetyl-coenzyme A (AcCoA) ([@R36]). Cells harboring *IDH1* mutations are defective in their ability to convert glutamine carbon to citrate and AcCoA ([@R17]). To this end, we cultured each HT1080 cell line in the presence of uniformly labeled ^13^C glutamine (\[U-^13^C~5~\]glutamine) and quantified the isotopologue distribution of metabolites in central carbon metabolism ([Figure 1C](#F1){ref-type="fig"}). We observed a significant decrease in M+5 citrate in R132C cells cultured in hypoxia compared with those expressing only functional WT IDH1, indicating that R132C-expressing cells were limited in their ability to generate citrate via reductive carboxylation (Figures [1D](#F1){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}). We also observed a concomitant increase in M+4 citrate in R132C cells, consistent with previously described reliance of IDH1-mutant cells on oxidative glutaminolysis in hypoxia ([Figures S1A and S1B](#SD1){ref-type="supplementary-material"}; [@R17]). We also observed altered labeling of aspartate from \[U-^13^C~5~\]glutamine that is consistent with decreased reductive carboxylation flux for generating cytosolic AcCoA (Figures [1E](#F1){ref-type="fig"} and [S1C](#SD1){ref-type="supplementary-material"}). This isogenic panel of HT1080 cells therefore recapitulates hallmarks of cancer cells expressing oncogenic IDH1 mutations. Notably, WT *IDH1* cells had the highest abundance of M+5 citrate and M+3 aspartate isotopologues, while PB and T77A cells (which have only one WT *IDH1* allele) had intermediate levels of these isotopologues ([Figures 1D and 1E](#F1){ref-type="fig"}).

Cytosolic NADPH Contributes to D2HG Production from IDH1^+/R132c^ Cells {#S4}
-----------------------------------------------------------------------

Basal *IDH1* enzymatic function can facilitate both production and consumption of NADPH and is decreased in *IDH1*-mutant cells ([@R15]; [@R54]; [@R64]), suggesting that cellular redox may be perturbed in these cells. To this end, we also observed elevated levels of Gly3P in R132C cells ([Figure 1B](#F1){ref-type="fig"}). To investigate how redox metabolism is altered by IDH1 mutation, we cultured cells in the presence of \[4-^2^H\]glucose and quantified enrichment on downstream metabolites ([Figure 2A](#F2){ref-type="fig"}). This tracer specifically labels cytosolic NADH via GAPDH, and these deuterons are subsequently transferred to lactate, malate, and Gly3P by downstream oxidoreductases ([@R29]). We observed similar labeling in all cells tested ([Figure 2B](#F2){ref-type="fig"}), indicating that no gross changes in NAD+ regeneration occurred upon perturbation of IDH1 activity.

We next examined how NADPH metabolism is altered in these HT1080 cell lines, as D2HG production by R132C IDH1 relies on the NADPH-dependent reduction of aKG. As NADPH and NADH pools are interconnected through transhydrogenase shuttles and enzymes ([@R9]), the redox pathways that support 2HG production are not well understood. Indeed, D2HG accumulates to high millimolar intracellular concentrations in IDH-mutant cells ([@R10]), and we observed a drastic increase in intracellular 2HG only in R132C cells ([Figure 2C](#F2){ref-type="fig"}). However, we also detected low levels of 2HG in cell lines expressing only WT IDH1 or enzymatically dead R132C-T77A IDH1 and hypothesized that L2HG was endogenously produced in these cells. To investigate the enantiomer of 2HG and source of reducing equivalents used for 2HG production in these cell lines, we cultured each cell type with \[4-^2^H\]glucose or \[3-^2^H\] glucose, which label NADH and NADPH respectively, and quantified 2HG labeling via gas chromatography-mass spectrometry (GC-MS) ([@R29]). Results were distinct in that \[4-^2^H\] glucose labeled approximately 10% of 2HG in PB, WT, and T77A cells, while \[3-^2^H\]glucose labeled \~15% of 2HG in R132C cells ([Figure 2D](#F2){ref-type="fig"}). These data suggest that L2HG is the predominant enantiomer present in cells expressing only WT IDH1, which has been demonstrated to be a byproduct of lactate dehydrogenase (LDH), malate dehydrogenase (MDH), or phosphoglycerate dehydrogenase (PHGDH) in cancer cells ([Figure 2E](#F2){ref-type="fig"}; [@R13]; [@R19], [@R20]). Notably, 2HG enrichment from \[3-^2^H\]glucose was similar to the expected enrichment of cytosolic NADPH calculated from fatty acid labeling ([Figure 3C](#F3){ref-type="fig"}; [@R29]). L2HG enrichment was significantly lower than that observed for lactate, malate, and Gly3P, suggesting that some 2HG is present in cells with WT IDH1. Ultimately, these results highlight the utility of deuterium tracing in assessing redox metabolism associated with altered IDH1 metabolism.

2HG Production Contributes Significantly to Cellular NADPH Demands {#S5}
------------------------------------------------------------------

We next attempted to estimate how D2HG production and other pathways contribute to NADPH demands within cells by quantifying 2HG secretion flux. *De novo* lipogenesis (DNL) has been estimated to be the largest consumer of NADPH in cultured cells ([@R12]). We measured DNL flux for fatty acid and cholesterol synthesis using \[1,2-^13^C~2~\]glucose and isotopomer spectral analysis and compared the NADPH requirements for DNL and 2HG ([Figure 3A](#F3){ref-type="fig"}). Strikingly, we found that the NADPH demand for D2HG production was relatively similar to that required for DNL ([Figure 3A](#F3){ref-type="fig"}). Importantly, most D2HG-associated NADPH consumption was from the efflux of D2HG. This increased NADPH demand did not affect palmitate synthesis in R132C cells at early time points in culture ([Figure S2A](#SD1){ref-type="supplementary-material"}). However, we did observe an increased uptake of \[^13^C\]palmitate from culture medium specifically in R132C cells, suggesting a potential reprogramming of lipid metabolism ([Figure S2B](#SD1){ref-type="supplementary-material"}).

We then asked if the consumption of NADPH by D2HG production influenced redox pathways associated with NADPH regeneration. The largest source of cytosolic NADPH in cells is the oxPPP ([@R63]). To probe any alterations in oxPPP redox function, we used a modeling approach to estimate the fraction of lipogenic NADPH supplied by the oxPPP ([Figure 3B](#F3){ref-type="fig"}; [@R29]). Despite the increased R132C-specific consumption of NAPDH by D2HG production, we found no change in the relative proportion of NADPH supplied by the oxPPP across these cell lines ([Figure 3C](#F3){ref-type="fig"}). We also observed no alteration in the balance of flux (i.e., pathway activity) diverted to the oxPPP and non-oxPPP to both glycolytic intermediates ([Figure S2C](#SD1){ref-type="supplementary-material"}) and biomass-derived ribose ([Figures S2D and S2E](#SD1){ref-type="supplementary-material"}), indicating that cells were able to compensate for D2HG synthesis by increasing lipid uptake only.

To control for any clonal effects associated with production of the cell line panel, we then inhibited D2HG production in the parental HT1080 cell line using AGI-5198, a pharmacological inhibitor of mutant IDH1 ([@R40]). We observed a\~90% reduction in 2HG/aKG levels with AGI-5198 addition, implying a reduction in NADPH consumption by D2HG production ([Figure 3D](#F3){ref-type="fig"}). However, inhibition of NADPH consumption did not alter NADPH supplied by oxPPP ([Figure 3E](#F3){ref-type="fig"}). Taken together our data indicate that D2HG production does not alter the contribution of oxPPP flux to redox homeostasis, as cells are able to sufficiently rewire pathways to compensate for the increased NADPH demand. Indeed, we also quantified the contribution of oxPPP flux to lipogenic NADPH using engineered HCT116 cells with knockin of mutant *IDH1*. IDH1^+/R132H^ HCT116 cells exhibited increased contributions of oxPPP to lipogenic NADPH pools ([Figure 3F](#F3){ref-type="fig"}), highlighting the ability of cells to reprogram redox pathways to meet the increased demands for NADPH caused by oncogenic D2HG production.

DNL Competes with D2HG Production for NADPH {#S6}
-------------------------------------------

Our results suggest that R132C cells are able to compensate for NADPH consumed by D2HG production under normal growth conditions. However, this metabolic defect could become a liability in the context of altered nutrient conditions. Recent work has demonstrated the utility in altering extracellular nutrient conditions to understand cancer-specific metabolic liabilities and sparked an interest in engineering more physiologic media ([@R4]). The tumor microenvironment is generally considered to be nutrient deficient, and tumor cells upregulate DNL to synthesize lipids necessary for growth ([@R1]). Indeed, lipogenesis is necessary for *in vitro* and *in vivo* tumor growth, and limitations in this pathway renders tumor cells more susceptible to chemotherapeutics ([@R46]). To this end, we hypothesized that removal of exogenous lipids from cell culture media could alter R132C-specific growth by limiting the NADPH available for DNL flux. We observed that R132C cell growth was specifically decreased in delipidated culture conditions ([Figure 4A](#F4){ref-type="fig"}). We also confirmed this growth phenotype in human oligodendroglioma (HOG) cells that ectopically express mutant IDH1 (Figures [4B](#F4){ref-type="fig"} and [S3A](#SD1){ref-type="supplementary-material"}). We then found that R132C cells exhibited decreased molar palmitate synthesis flux, suggesting the observed growth defect was mediated by an inability to synthesize enough lipids ([Figure 4C](#F4){ref-type="fig"}).

We then asked what specific metabolic liability could be causing DNL defect in R132C cells. DNL is critical biosynthetic process that requires the coordination of many enzymes and sufficient anabolic substrates (i.e., AcCoA and NADPH). As many possible factors could decrease DNL, we investigated potential drivers of this observed growth defect ([Figure 4A](#F4){ref-type="fig"}). 2HG has been widely characterized as an inhibitor of aKG-dependent dioxygenase class enzymes that include important epigenetic modifiers (i.e., demethylases) ([@R14]; [@R32]; [@R49]; [@R56]). We observed that expression of genes associated with fatty acid synthesis was not altered in R132C cells, implying that the production of D2HG, rather than a downstream epigenetic modification, caused the growth defect ([Figure S3B](#SD1){ref-type="supplementary-material"}). We also observed no alteration in the contribution of oxPPP flux to lipogenic NADPH, indicating that other redox pathways were not distinctly compensating ([Figure S3C](#SD1){ref-type="supplementary-material"}). We detected a slight increase in glucose contribution to lipogenic AcCoA, consistent with 2HG production shunting glutamine carbon away from DNL ([Figure S3D](#SD1){ref-type="supplementary-material"}). We also observed a concomitant increase in glutamine uptake in R132C cells cultured under delipidated conditions that could support 2HG production without limiting carbon for DNL ([Figure S3D](#SD1){ref-type="supplementary-material"}). Alterations in glutamine metabolism independent of 2HG production were observed in T77A double-mutant cells ([Figure S3D](#SD1){ref-type="supplementary-material"}), consistent with altered central carbon metabolite abundance ([Figure S3E](#SD1){ref-type="supplementary-material"}). Further work must be done to understand how loss of WT *IDH1* enzymatic activity reprograms metabolism to support DNL. Taken together, these changes are unlikely to account for the altered cell growth in delipidated conditions.

On the other hand, the desaturation index (C18:1/C18:0) quantified from total fatty acids in each cell line was significantly decreased in R132C cells ([Figure 4D](#F4){ref-type="fig"}). Production of desaturated fatty acid species requires SCD activity, molecular oxygen, and NADPH ([@R26]; [@R60]). Because we did not detect changes in SCD expression ([Figure S2B](#SD1){ref-type="supplementary-material"}) and molecular oxygen is not limiting under normoxic conditions, this result suggests that NADPH was limiting R132C cells and could explain the decreased palmitate synthesis observed in R132C cells ([Figure 4B](#F4){ref-type="fig"}). Importantly, we observed a dramatic increase in cholesterol biosynthesis with serum delipidation ([Figure 4E](#F4){ref-type="fig"}). The NADPH requirements for cholesterol synthesis (26 molecules per cholesterol molecule) is a significant biosynthetic sink for NADPH, highlighting the importance of both fatty acid and sterol synthesis in contributing to the redox needs of proliferating cancer cells.

To better understand how NADPH regeneration fluxes were altered, flux through glycolysis and the oxPPP were quantified across the cell panel. We observed increased glycolytic fluxes in both R132C and T77A cells compared with WT ([Figure 4F](#F4){ref-type="fig"}). Increased glycolytic flux is generally associated with altered mitochondrial state, but our data suggest that mitochondrial pathways are maintained by reprogramming of glutamine metabolism ([@R17]). However, increased glucose uptake can also result in elevated oxPPP flux if branching is unchanged. We cultured cells in the presence of \[1,2-^13^C\]glucose tracer to understand the relative shunting of glucose carbon through glycolysis and the oxPPP ([@R28]). We observed no difference in relative shunting to the oxPPP across the cell lines ([Figure S2G](#SD1){ref-type="supplementary-material"}). However, when combined with the increased glucose uptake and lactate efflux detected in R132C cells, these data indicate that oxPPP activity is significantly increased to meet the additional NADPH demands for D2HG production ([Figure 4G](#F4){ref-type="fig"}). Importantly, R132C cells increase glucose uptake and oxPPP flux to a greater extent than T77A cells, implying that oxPPP flux and NADPH production is further increased to support D2HG production ([Figure 4G](#F4){ref-type="fig"}). In turn, the cells are unable to fully compensate for these NADPH demands and growth is reduced in lipid-deficient conditions.

Finally, we investigated whether pharmacological inhibition of 2HG production by AGI-5198 could alter growth in delipidated conditions. Administration of AGI-5198 *in vitro* did not improve growth under such conditions and slightly decreased cell growth ([Figure S4A](#SD1){ref-type="supplementary-material"}). Additionally, inhibition of 2HG production by AGI5198 did not alter the desaturation index of cellular fatty acids, suggesting that NADPH availability was not sufficiently altered ([Figure S4B](#SD1){ref-type="supplementary-material"}). As AGI-5198 does not completely block 2HG production at concentrations routinely used *in vitro* and could also inhibit WT enzyme activity ([Figure 3D](#F3){ref-type="fig"}), further studies are needed to understand how inhibition of mutant IDH1 might influence the redox sensitivity of tumor cells in the context of combinatorial treatments.

DISCUSSION {#S7}
==========

The unique nature of IDH-mutant tumors has motivated a large research effort to identify potential targets within their signaling and metabolic networks ([@R7]; [@R41]; [@R50]; [@R52]). The dramatic accumulation of 2HG in these tumors has focused much attention on the role of aKG-dependent dioxygenases in driving tumorigenesis ([@R31]). However, as IDH1 and IDH2 play critical roles in TCA metabolism and redox homeostasis, a greater understanding of the metabolic reprogramming required to support this unique liability may yield clues to additional therapeutic opportunities ([@R37]). Such metabolic alterations could explain why genetic disruption of mutant *IDH1* affects the growth of some cells but not pharmacological inhibition ([@R24], [@R25]).

Maintenance of redox homeostasis is essential for proper cell function, as pyridine nucleotides orthogonally connect bioenergetic and biosynthetic metabolic pathways ([@R2]). Specifically, the regeneration of NADPH is required for anabolism of lipids, DNA, and proline as well as maintenance of reduced glutathione pools ([@R12]). However, the role of *IDH1* in the maintenance of redox homeostasis has been underappreciated. *IDH1* can functionally participate in a redox shuttle that interconnects mitochondrial and cytosolic NAD(P)H pools ([@R42]). Indeed, this shuttle has been demonstrated to be critical for redox homeostasis in anchorage-independent conditions ([@R23]). Upregulation of *IDH1* can promote the survival of pancreatic cancer cell lines under nutrient-limited conditions ([@R61]). However, the largest source of NADPH in the cell is the oxPPP ([@R12]; [@R29]; [@R63]). Targeting of oxPPP enzymes is particularly deleterious to growth of cancer cell lines ([@R30]; [@R39]; [@R65]), and coordinated therapeutic strategies that induce redox stress (e.g., nutrient modulation, radiation) while inhibiting pathways that promote redox homeostasis may be particularly effective ([@R8]). Specifically, we highlight the importance of exogenous lipid availability in influencing cellular redox pathways, such that the increased NADPH requirements for fatty acid and sterol synthesis compromise growth of cell lines expressing mutant IDH1.

Our work suggests that IDH1-mutant tumor cells may be susceptible to therapeutic strategies that promote oxidative stress (albeit in cell culture); however, more extensive testing in animals is required to realize the translational potential of such approaches. We found that D2HG production is a major sink for NADPH, which is needed for reductive biosynthesis and redox homeostasis. When cells are challenged by lipid deficiency that drives cells to upregulate DNL flux, D2HG production becomes a metabolic liability that limits growth. Similar findings have recently been reported using engineered HCT116 cells ([@R16]). Other pathways have also been described to compensate for such redox defects. For example, *IDH1* mutant glioma cells maintain redox homeostasis by enhancing the mitochondrial production of proline ([@R18]). Metabolic profiling of low-grade gliomas has also correlated tumor progression with altered redox state ([@R22]). Additional studies are needed to understand if this redox sensitivity can be exploited in vivo. Recent work has demonstrated that D2HG can inhibit branched-chain amino acid transaminases (BCATs), compromising glutathione synthesis and sensitizing tumors to radiotherapy in combination with glutaminase inhibition ([@R35]). Such studies reinforce the concept that IDH mutations can reprogram the metabolic network to sensitize tumors to combinatorial therapies. Our studies highlight the importance of reducing equivalent availability in lipid biosynthesis. Although DNL is required for growth of lung tumors as xenografts or in genetically engineered mouse models ([@R46]), the lipogenic requirements of sarcomas, gliomas, and other IDH1-mutant tumors may be different. Furthermore, the impact of dietary fat and combination therapies using mutant IDH1 inhibitors and/or radiation must be considered to appreciate the therapeutic potential of these findings. Nevertheless, our results highlight the impact of lipogenesis and D2HG production on cellular redox pathways.

STAR⋆METHODS {#S8}
============

KEY RESOURCES TABLE {#S9}
-------------------

  REAGENT or RESOURCE                                                       SOURCE                     IDENTIFIER
  ------------------------------------------------------------------------- -------------------------- ----------------------------------------------
  Chemicals, Peptides, and Recombinant Proteins                                                        
  \[1,2-^13^C\]glucose                                                      Cambridge Isotope Labs     CLM-504
  \[3-^2^H\]glucose                                                         Omicron Biochemicals       GLC-034
  \[4-^2^H\]glucose                                                         Omicron Biochemicals       GLC-035
  \[U-^13^C~6~\]glucose                                                     Cambridge Isotope Labs     CLM-1396
  \[U-^13^C~5~\]glutamine                                                   Cambridge Isotope Labs     CLM-1822
  Critical Commercial Assays                                                                           
  RNeasy Mini Kit                                                           QIAGEN                     74104
  cDNA Reverse Transcription Kit                                            Thermo Fisher Scientific   4368814
  Cyquant Cell Proliferation Assay                                          Thermo Fisher Scientific   C7026
  Experimental Models: Cell Lines                                                                      
  HCT116 parental and IDH1 knock-in clones (2H1, 2A9)                       Horizon Discovery          N/A
  HT1080                                                                    ATCC                       N/A
  HT1080 IDH1 panel                                                         [@R33]                     <https://doi.org/10.18632/oncotarget.3330>
  Human oligodendroma IDH1 panel                                            [@R35]                     <https://doi.org/10.1016/j.cell.2018.08.038>
  Oligonucleotides                                                                                     
  RT-PCR primers, see [Table S2](#SD1){ref-type="supplementary-material"}   Primerbank                 N/A
  Software and Algorithms                                                                              
  INCA                                                                      [@R59]                     <https://mfa.vueinnovations.com/>

CONTACT FOR REAGENT AND RESOURCE SHARING {#S10}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Christian Metallo (<cmetallo@ucsd.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S11}
--------------------------------------

### Cell Lines and Culture Conditions {#S12}

HT1080 and HCT116 cells were grown in DMEM supplemented with 10% FBS and 100 U/mL penicillin/streptomycin. HOG cells were grown in IMDM supplemented with 10% FBS, 100 U/mL penicillin/streptomycin, and 200 μg/mL hygromyocin (McBrayer et al.). HT1080 parental cells were obtained from ATCC. HCT116 parental and IDH1 knock-in clones (+/R132C; 2H1 and 2A9) were obtained from Horizon Discovery. Cells were maintained in humidified incubator at 5% CO~2~. For hypoxia experiments, cells were maintained in humidified glove box (Coy) at 5% CO~2~ and 1% O~2~.

METHOD DETAILS {#S13}
--------------

### Cell growth and stable isotope tracing {#S14}

For delipidated cell growth experiments, cells were plated in basal media. Fibrosarcoma cells were then allowed to adhere for 4 hours and then media was exchanged to delipidated media. HOG cells were allowed to adhere overnight and then media was exchanged to delipidated media. Cell growth was measured by either using hemocytometer for final cell counts or using Cyquant Cell Proliferation Assay (Molecular Probes) for estimation of DNA abundance, per manufacturer's protocol.

For isotopic labeling experiments, cells were plated in basal growth experiments and then rinsed with PBS before addition of tracing media. Cells were cultured in glucose- and glutamine-free media (GIBCO) supplemented with 10% dialyzed FBS, 100 U/mL penicillin/streptomycin, 4mM glutamine, and 25mM glucose. For glutamine tracing, cells were supplied ^12^C glucose (Sigma) and \[U-^13^C~5~\]glutamine (99%, Cambridge Isotope Laboratories). For glucose tracing, cells were supplied ^12^C glutamine (Sigma) and either \[3-^2^H\]glucose (99%, Cambridge Isotope Laboratories), \[4-^2^H\]glucose (99%, Omicron Biochemicals), \[U-^13^C~6~\] glucose (99%, Cambridge Isotope Laboratories), or \[1,2-^13^C\]glucose (99%, Cambridge Isotope Laboratories). For palmitate uptake, \[U-^13^C~16~\]palmitate (99%, Cambridge Isotope Laboratories) was bound to fatty-acid free albumin (Roche) as previously described and supplied to cells at 50 μM (5% v/v) ([@R51]). For delipidated tracing experiments, media was prepared in same way except using 10% dialyzed and delipidated FBS.

### Delipidation of FBS {#S15}

Normal or dialyzed FBS (GIBCO) was delipidated by first stirring 20 mg/mL fumed silica (Sigma) for 3 hr in ambient conditions. FBS slurry was then clarified by repeated centrifugation at 2000 g for 20 min. Supernatant was then sterile filtered (0.2 mm), aliquoted, and stored at ^\_^20C for future use.

### Metabolite Extraction and GC-MS Analysis {#S16}

Cells were rinsed with 0.9% (w/v) saline and 250 μL of ---80⁰C MeOH was added to quench metabolic reactions. 100 μL of ice-cold water supplemented with 10 μg/mL norvaline was then added to each well and cells were collected by scraping. The lysate was moved to a fresh 1.5 mL sample tube and 250 μL of ---20⁰C chloroform supplemented with 4 μg/mL D31 palmitate (and 4 μg/mL coprostan-3-ol if quantifying cholesterol) was added. After vortexing and centrifugation, the top aqueous layer and bottom organic layer were collected and dried under airflow. For analysis of cellular biomass, remaining interfacial layer was isolated, washed twice with methanol, and allowed to dried overnight with ambient airflow ([@R3]).

Derivatization of aqueous metabolites was performed using the Gerstel MultiPurpose Sampler (MPS 2XL). Methoxime- derivatives were formed by addition of 15 μL 2% (w/v) methoxylamine hydrochloride (MP Biomedicals) in pyridine and incubated at 45C for 60 minutes. Samples were then silylated by addition of 15 mL of N-tert-butyldimethylsily-N-methyltrifluoroacetamide (MTBSTFA) with 1% tert-butyldimethylchlorosilane (tBDMS) (Regis Technologies) and incubated at 45⁰C for 30 minutes. Aqueous metabolites were analyzed by GC-MS using a DB-35MS column (30 m x 0.25mm i.d. x 0.25 mm, Agilent J&W Scientific, Santa Clara, CA) installed in an Agilent 7890B gas chromatograph (GC) interfaced with a 5977C mass spectrometer (MS). For separation of aqueous metabolites, the GC oven was held at 100⁰C for 1 min after injection, increased to 255⁰C at 3.5⁰C/min, and finally increased to 320⁰C at 15⁰C/min and held for 3 min. Electron impact ionization was performed with the MS scanning over the range of 100--650 m/z.

Dried organic fraction was saponified and esterified to form fatty acid methyl esters (FAMEs) by addition of 500 μL of 2% (w/v) H~2~SO~4~ in MeOH and incubated at 50⁰C for 120 minutes. FAMEs were then extracted by addition of saturated NaCl and hexane before collection and drying of the inorganic layer. Derivatized fatty acids were analyzed by GC-MS using a select FAME column (100 m x 0.25mm i.d. x 0.25 μm; Agilent J&W Scientific) installed in an Agilent 7890A gas chromatograph (GC) interfaced with a 5975C mass spectrometer (MS). For separation the GC oven was held at 80⁰C for 1 min after injection, increased to 160⁰C at 20⁰C/min, increased to 198⁰C at 1⁰C/min, and finally increased to 250⁰C at 5⁰C/min and held for 15 min. Electron impact ionization was performed with the MS scanning over the range of 120--400 m/z. For cholesterol measurements, saponified organic phase was then redried under airflow and derivatized using a Gerstel autosampler by addition of 15 μL of N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA; MachereyNagel) and incubated at 45⁰C for 30 minutes. Cholesterol was was analyzed by GC-MS using a DB-35MS column (30 m x 0.25mm i.d. x 0.25 μm, Agilent J&W Scientific, Santa Clara, CA) installed in an Agilent 7890B gas chromatograph (GC) interfaced with a 5977C mass spectrometer (MS). For separation, the GC over was held at 150⁰C for 1 min after injection, increased to 260⁰C at 20⁰C/min and held for 3 min, and then increased to 280⁰C at 10⁰C/min and held for 15 min. Electron impact ionization was performed with the MS scanning over the range of 70--800 m/z.

Cellular biomass was hydrolyzed with 2N HCl for 2 hr at 80⁰C to release ribose monomers and then dried under airflow. Dried samples were then dissolved in 200 μL 2% (w/v) hydroxylamine hydrochloride in pyridine (Sigma) and incubated at 90C for 60 min. Next, 100 μL of propionic anhydride was added and samples were incubated at 60⁰C for 30 min. Samples were then evaporated under airflow at 60⁰C and resuspended in 100 μL ethyl acetate. Aldonitrile pentapropionate derivatives were then analyzed by GC-MS using a DB-35MS column (30 m x 0.25mm i.d. x 0.25 μm, Agilent J&W Scientific, Santa Clara, CA) installed in an Agilent 7890B gas chromatograph (GC) interfaced with a 5977C mass spectrometer (MS). For separation, the GC over was held at 100⁰C for 1 min after injection and then increased to 255⁰C at 20⁰C/min and held for 4 min. Electron impact ionization was performed with the MS scanning over the range of 120--650 m/z.

### Metabolite integration and isotopomer spectral analysis (ISA) {#S17}

Isotopologue distributions and total abundances were determined by integration of mass fragments ([Table S1](#SD1){ref-type="supplementary-material"}) and correcting for natural abundances using in-house MATLAB-based algorithm.

Isotopomer spectral analysis (ISA) was performed to estimate contribution of oxPPP to cytosolic NADPH as previously described ([@R29]). ISA compares experimental labeling of palmitate after 72 hr trace with \[3-^2^H\]glucose to simulated labeling using a reaction network where C16:0 is condensation of 14 NADPHs. Parameters for contribution of *PGD* to lipogenic NADPH (D value) and percentage of newly synthesized fatty acid (g(t) value) and their 95% confidence intervals are then calculated using best-fit model from INCA MFA software ([@R59]). Contribution of oxPPP was then estimated by doubling D value to account for stoichiometry of the oxPPP pathway.

Estimation of contribution of ^13^C tracers to lipogenic AcCoA and palmitate synthesis was conducted as similar method to oxPPP contribution. Experimental fatty acid labeling from \[U-^13^C~6~\]glucose, \[U-^13^C~5~\]glutamine, or \[1,2-^13^C\]glucose after 24--72 hr trace was compared to simulated labeling using a reaction network where C16:0 is condensation of 8 AcCoA. ISA data plotted as mean ± 95% CI. \* indicates statistical significance by non-overlapping confidence intervals.

Estimation of cholesterol synthesis was similarly conducted. Experimental cholesterol labeling from \[1,2-^13^C\]glucose or \[U-^13^C~5~\] glutamine after 24 hr trace was to compared to simulated labeling using a previously described reaction network ([@R27]). ISA data plotted as mean ± 95% CI.

### Measurement of extracellular and intracellular fluxes {#S18}

Initial and final concentrations of extracellular glucose, lactate, glutamine, and glutamate were determined by Yellow Springs Analyzer 2950 instrument. In parallel, cells were plated for initial and final cell counts. Plated cells were pre-adapted to delipidated DMEM media for 24 hr before experiment.

The extracellular fluxes were described by the following differential equations: $$\frac{dX}{dt} = \mu X$$ $$\frac{dN_{i}}{dt} = q_{i}X$$ $$\frac{dN_{gln}}{dt} = q_{i}X - kN_{gln}$$ where, X is concentration of cells, m is cellular growth (hr^−1^), N is extracellular moles of metabolite i present, q~i~ is cell-specific consumption rate of metabolite i (mol/cell-hr), and k is first-order degradation rate of glutamine in cell culture (hr^−1^). k was set to 0.0045 hr^−1^ as determined in literature ([@R48]).

Solution of ODEs yielded the following equations which we used to find extracellular fluxes: $$X = X_{0}e^{\mu t}$$ $$q_{i} = \frac{\mu\left( {N_{i} - N_{i,0}} \right)}{X - X_{0}}$$ $$q_{gln} = \frac{N_{gln} - N_{gln,0}e^{- kt}}{\left( \frac{1}{\mu + k} \right)\left( {X - X_{0}e^{- kt}} \right)}$$ where subscript 0 signifies initial concentration.

For oxPPP measurement, glucose uptake measurement was coupled to ratio of (M1/(M1 + M2)) lactate label from \[1,2-^13^C\] glucose tracer. This measurement is only appropriate when (1) considering relative differences across similar experimental conditions and (2) assuming that non-oxPPP flux and biosynthetic demands of ribose are not altered between conditions.

### NADPH consumption {#S19}

For fatty acid synthesis, consumption was defined as NADPH flux required to support biosynthesis of myristate (C14:0), palmitate (C16:0), stearate (C18:0), and oleate (C18:1) as these are predominantly synthesized species ([@R12]). Cells were traced with \[1,2-^13^C\]glucose for 24 hr and extracted for intracellular metabolites. In parallel, initial and final cell counts were taken. Per cell molar abundance of fatty acid species was determined by GC/MS. Percentage newly synthesized fatty acid was determined by ISA with reaction network where C14:0 is condensation of 7 AcCoA, C16:0 is condensation of 8 AcCoA, C18:0 is condensation of 9 AcCoA, and C18:1 is condensation of 9 AcCoA. Molar fatty acid synthesis flux was then calculated by dividing molar newly synthesized fatty acids by integral viable cell density over experimental time period. NADPH flux was then calculated by stoichiometric requirement of 12 NADPH per myristate, 14 NADPH per palmitate, 16 NADPH per stearate, and 17 NADPH per oleate.

For cholesterol, percentage newly synthesized was determined by ISA as stated above. Molar cholesterol synthesis flux was then calculated by dividing molar newly synthesized cholesterol by integral viable cell density over experimental time period. NADPH flux was then calculated by stoichiometric requirement of 26 NADPH per cholesterol.

For 2HG production fluxes, consumption was defined as NADPH flux required to support 2HG efflux and maintenance of intracellular abundance. Initial and final concentrations of extracellular 2HG were determined by GCMS analysis and use of external standard curves. Per cell molar abundance of 2HG was determined by GCMS at final time point. Efflux was then calculated similarly as above and dilutive flux was calculated by dividing intracellular concentration by specific growth rate. NADPH flux was then calculated by stoichiometric requirement of one NADPH per 2HG.

### RT-PCR {#S20}

Total mRNA was isolated from cells using RNA isolation kit (RNeasy Mini Kit; QIAGEN). Isolated RNA was reverse transcribed using cDNA synthesis kit (High-capacity cDNA Reverse Transcription Kit; Thermo Fisher Scientific). Real-time PCR was performed using SYBR green reagent (iTaq Universal SYBR Green Supermix; Bio-Rad). Relative expression was determined using Livak (ΔΔCT) method with *GAPDH* as housekeeping gene. Primers used were taken from Primerbank ([@R53]) and tabulated in [Table S2](#SD1){ref-type="supplementary-material"}. All commercial kits were used per the manufacturer's protocol.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S21}
---------------------------------------

Unless indicated, all results shown as mean ± SEM of biological triplicates. P values were calculated using a Student's two-tailed t test; \*, P value between 0.01 and 0.05; \*\*, P value between 0.001 and 0.01; \*\*\*, P value less than 0.001. Unless indicated, all normalization and statistical tests compared to WT cells.
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![Metabolic Characterization of Isogenic IDH1-Expressing HT1080 Cell Lines\
(A) Depiction of enzymatic activity present in each cell line.\
(B) Relative intracellular abundance of glycolytic intermediates, TCA cycle metabolites, and amino acids (n = 6). Normalized to PB.\
(C) Atom transition map of \[U-^13^C~5~\]glutamine for reductive and oxidative metabolism. Glutaminase and transamination of glutamate to aKG require concomitant amination of keto-acids (KA) to amino acids (AA) (e.g., Asp, Ala, Pro, Ser). Oxidative TCA flux leads to M+4 citrate. Reductive carboxylation of aKG leads to the M+5 citrate and subsequently M+3 aspartate.\
(D) Percentage of M+5 citrate from \[U-^13^C~5~\]glutamine in normoxia and hypoxia.\
(E) Percentage of M+3 aspartate from \[U-^13^C~5~\]glutamine in normoxia and hypoxia.\
In (B), (D), and (E), data are plotted as mean ± SEM. Unless indicated, all data represent biological triplicates. See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1511532-f0002){#F1}

![Tracing NAD(P)H Regeneration and 2HG Production in HT1080-IDH1 Cell Lines\
(A) Atom transition map of \[4-^2^H\]glucose. The tracer labels cytosolic NADH through GAPDH, leading to downstream labeling through lactate dehydrogenase (LDH), malate dehydrogenase (MDH), and glycerol-3-phosphate dehydrogenase (Gly3PDH).\
(B) Percentage M+1 label from \[4-^2^H\]glucose is not altered by *IDH1* status.\
(C) Relative intracellular abundance of 2-hydroxyglutarate is increased in R132C cells.\
(D) Percentage M+1 2HG label from \[4-^2^H\]glucose and \[3-^2^H\]glucose.\
(E) Depiction of L2HG and D2HG production by NAD(P)H.\
In (B)--(D), data are plotted as mean ± SEM. Unless indicated, all data represent biological triplicates.](nihms-1511532-f0003){#F2}

![D2HG Production and Secretion Increase NADPH Demands in IDH1^+/R132C^ Cells\
(A) NADPH consumption fluxes by lipid synthesis and 2HG production in fibrosarcoma panel.\
(B) Atom transition map of \[3-^2^H\]glucose.\
(C) Contribution of oxPPP to cytosolic NADPH in fibrosarcoma panel.\
(D) 2HG abundance in parental HT1080 cells upon treatment with 10 mM AGI-5198.\
(E) Contribution of oxPPP to cytosolic NADPH in parental HT1080 cells with 10 mM AGI-5198.\
(F) Contribution of oxPPP to cytosolic NADPH in non-native IDH1-R132H engineered HCT116 cells.\
In (A), (C), (E), and (F), data are plotted as mean ± 95% confidence interval (CI). \*Statistical significance by non-overlapping confidence intervals. In (D), data are plotted as mean ± SEM. Unless indicated, all data represent biological triplicates. See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1511532-f0004){#F3}

![D2HG Production Limits NADPH for DNL in Lipid-Deficient Conditions\
(A) Normalized cell number of fibrosarcoma panelafter 48 hr in delipidated conditions.\
(B) Normalized cell number of HOG panel ectopically expressing *IDH1* after 96 hr in delipidated conditions.\
(C) Normalized molar palmitate synthesis flux infibrosarcoma panel.\
(D) Normalized desaturation index (C18:1/C18:0) in fibrosarcoma panel.\
(E) Percentage newly synthesized cholesterol after24 hr in control or delipidated conditions in fibrosarcoma panel.\
(F) Extracellular glucose uptake and lactate effluxin fibrosarcoma panel.\
(G) Normalized oxPPP flux in delipidated conditions in fibrosarcoma panel.\
In (A)--(D), (F), and (G), data are plotted as mean ± SEM. In (E), data are plotted as mean ± 95% CI. Unless indicated, all data represent biological triplicates. See also [Figures S3 and S4](#SD1){ref-type="supplementary-material"}.](nihms-1511532-f0005){#F4}

###### Highlights

-   D2HG production competes with reductive biosynthesis for NADPH in IDH1-mutant cells

-   ^2^H tracing resolves L2HG and D2HG production pathways

-   IDH1 mutation slows cell growth when biosynthetic NADPH demands are increased
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